3/25
01:01 pm
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $48.00 price target on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $48.00 price target on the stock.
3/22
12:00 pm
imvt
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday [Yahoo! Finance]
Low
Report
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday [Yahoo! Finance]
3/21
07:06 am
imvt
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/20
04:16 pm
imvt
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Medium
Report
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
3/13
01:32 pm
imvt
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report? [Yahoo! Finance]
3/13
08:16 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $50.00 price target on the stock.
3/12
07:38 am
imvt
Immunovant Awarded U.S. Patent for IMVT-1402 [Yahoo! Finance]
Low
Report
Immunovant Awarded U.S. Patent for IMVT-1402 [Yahoo! Finance]
3/12
07:30 am
imvt
Immunovant Awarded U.S. Patent for IMVT-1402
Low
Report
Immunovant Awarded U.S. Patent for IMVT-1402
3/8
11:09 am
imvt
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks [Yahoo! Finance]
Low
Report
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks [Yahoo! Finance]
2/23
11:40 pm
imvt
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares [Yahoo! Finance]
Medium
Report
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares [Yahoo! Finance]
2/20
07:33 am
imvt
S&P 500 Futures Decline in Premarket Trading; Discover Finl Svcs, GlobalFoundries Lead [MarketWatch]
Low
Report
S&P 500 Futures Decline in Premarket Trading; Discover Finl Svcs, GlobalFoundries Lead [MarketWatch]
2/20
07:17 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $51.00 price target on the stock.
2/20
07:17 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $51.00 price target on the stock.
2/15
07:17 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $55.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $55.00 price target on the stock.
2/14
05:22 am
imvt
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth [Yahoo! Finance]
Medium
Report
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth [Yahoo! Finance]
2/14
04:50 am
imvt
Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs [Yahoo! Finance]
Medium
Report
Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs [Yahoo! Finance]
2/12
07:13 am
imvt
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 [Yahoo! Finance]
Medium
Report
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 [Yahoo! Finance]
2/12
07:00 am
imvt
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
Medium
Report
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
1/22
06:15 am
imvt
Should You Invest in Immunovant (IMVT)? [Yahoo! Finance]
Low
Report
Should You Invest in Immunovant (IMVT)? [Yahoo! Finance]
1/16
06:31 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/3
08:00 am
imvt
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Medium
Report
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/29
11:41 am
imvt
Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 [Seeking Alpha]
Low
Report
Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 [Seeking Alpha]